Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin‐induced thrombocytopenia | Zendy

Pinto Duane S. | Zendy; Sperling Robert T. | Zendy; Tu Thomas M. | Zendy; Cohen David J. | Zendy; Carrozza Joseph P. | Zendy

Premium

Combination platelet glycoprotein IIb/IIIa receptor and lepirudin administration during percutaneous coronary intervention in patients with heparin‐induced thrombocytopenia

Author(s) -

Pinto Duane S.,

Sperling Robert T.,

Tu Thomas M.,

Cohen David J.,

Carrozza Joseph P.

Publication year - 2003

Publication title -

catheterization and cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.988

H-Index - 116

eISSN - 1522-726X

pISSN - 1522-1946

DOI - 10.1002/ccd.10393

Subject(s) - medicine , eptifibatide , lepirudin , abciximab , tirofiban , bivalirudin , percutaneous coronary intervention , discovery and development of direct thrombin inhibitors , direct thrombin inhibitor , heparin , conventional pci , heparin induced thrombocytopenia , clopidogrel , platelet , cardiology , thrombin , aspirin , myocardial infarction , dabigatran , warfarin , atrial fibrillation

We evaluated a combination therapy using glycoprotein IIb/IIIa receptor antagonism and direct thrombin inhibition in nine patients with heparin‐induced thrombocytopenia (HIT) undergoing 10 percutaneous coronary interventions (PCIs). In selected patients with HIT, the combination of a direct thrombin inhibitor, lepirudin, and abciximab, tirofiban, or eptifibatide appears to be a safe and effective anticoagulation strategy for PCI. Cathet Cardiovasc Intervent 2003;58:65–68. © 2003 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research